Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating
Moomoo News13:31 ET · Ratings
Baird Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $26
Moomoo News13:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
TipRanks13:30 ET · Ratings
Enanta Pharmaceuticals (ENTA) Gets a Hold From Leerink Partners
TipRanks13:17 ET · Ratings
Enanta Pharma Analyst Ratings
BenzingaSep 27 10:46 ET · Ratings
Enanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323
TipRanksSep 26 16:15 ET · Ratings

Comments

Moomoo AI

Mar 6 10:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

1

Moomoo AI

Feb 12 19:23

Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported And Analysts Have Been Cutting Their Estimates

Moomoo AI

Jan 18 18:42

The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Moomoo AI

Dec 17, 2023 20:41

Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.

Independent Director Of Enanta Pharmaceuticals Sold 73% Of Their Shares

Explore moomoo's "Insider Activity" for institutional sentiment

Analysts Notebook

Jul 6, 2022 20:10

Columns Top upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more

Upgrades
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...

8

ENTA Enanta Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target